0000950123-24-009204 Sample Contracts
SUMMARY OF BASIC LEASE INFORMATIONLease • September 12th, 2024 • Sionna Therapeutics, Inc. • Pharmaceutical preparations
This Lease, which includes the preceding Summary and the exhibits attached hereto and incorporated herein by this reference (the Lease, the Summary and the exhibits to be known sometimes collectively hereafter as the “Lease”), dated as of the date set forth in Section 1 of the Summary, is made by and between BP3-BOS6 21 HICKORY LLC, a Delaware limited liability company (“Landlord”), and SIONNA THERAPEUTICS, INC., a Delaware corporation (“Tenant”).
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF...License Agreement • September 12th, 2024 • Sionna Therapeutics, Inc. • Pharmaceutical preparations • New York
This License Agreement (this “Agreement”) is made and entered into as of December 20, 2019 (the “Effective Date”) by and between Sanofi, a French corporation (acting on its own behalf and on behalf of its Affiliates, “Sanofi”) and Sling Therapeutics, Inc., a Delaware corporation (“Licensee”). Sanofi and Licensee are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF...License Agreement • September 12th, 2024 • Sionna Therapeutics, Inc. • Pharmaceutical preparations • New York
This License Agreement (this “Agreement”) is made and entered into effective July 11, 2024 (the “Effective Date”) by and between AbbVie Global Enterprises Ltd., a corporation organized under the laws of Bermuda and having a principal place of business at Thistle House, 4 Burnaby Street, Hamilton Pembroke HM 11, Bermuda (“AbbVie”), and Sionna Therapeutics, Inc., a Delaware corporation and having a principal place of business at 21 Hickory Drive, Suite 500, Waltham, MA 02451 (“Sionna”). AbbVie and Sionna are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF...Payment Agreement • September 12th, 2024 • Sionna Therapeutics, Inc. • Pharmaceutical preparations • New York
This Payment Agreement (this “Agreement”) is made and entered into as of December 20, 2019 (the “Effective Date”) by and between Cystic Fibrosis Foundation, a Delaware not-for-profit corporation (“CFF”) and Sling Therapeutics, Inc., a Delaware corporation (“Sling”). CFF and Sling are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”